Switch theme
Sign up to access all valuation multiples
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
1998
2.7K+
LTM Revenue $3.4B
LTM EBITDA $1.2B
$9.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genmab has a last 12-month revenue of $3.4B and a last 12-month EBITDA of $1.2B.
In the most recent fiscal year, Genmab achieved revenue of $3.3B and an EBITDA of $1.5B.
Genmab expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genmab valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.5B | $3.3B | XXX | XXX | XXX |
| Gross Profit | n/a | $2.5B | XXX | XXX | XXX |
| Gross Margin | NaN% | 75% | XXX | XXX | XXX |
| EBITDA | $907M | $1.5B | XXX | XXX | XXX |
| EBITDA Margin | 36% | 45% | XXX | XXX | XXX |
| Net Profit | $841M | $663M | XXX | XXX | XXX |
| Net Margin | 34% | 20% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 28, 2025, Genmab's stock price is DKK 1347 (or $205).
Genmab has current market cap of DKK 83.9B (or $12.8B), and EV of DKK 63.9B (or $9.7B).
See Genmab trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.7B | $12.8B | XXX | XXX | XXX | XXX | $17.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 28, 2025, Genmab has market cap of $12.8B and EV of $9.7B.
Genmab's trades at 2.8x LTM EV/Revenue multiple, and 8.2x LTM EBITDA.
Analysts estimate Genmab's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Genmab and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $9.7B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 6.6x | XXX | XXX | XXX |
| P/E | 10.7x | XXX | XXX | XXX |
| P/E/Growth | -76.1x | XXX | XXX | XXX |
| EV/FCF | 8.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGenmab's NTM/LTM revenue growth is 15%
Genmab's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Genmab's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Genmab's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Genmab and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 45% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 63% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 60% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 45% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 63% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genmab acquired XXX companies to date.
Last acquisition by Genmab was XXXXXXXX, XXXXX XXXXX XXXXXX . Genmab acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Genmab founded? | Genmab was founded in 1998. |
| Where is Genmab headquartered? | Genmab is headquartered in Denmark. |
| How many employees does Genmab have? | As of today, Genmab has 2.7K+ employees. |
| Who is the CEO of Genmab? | Genmab's CEO is Dr. Jan G. J. van de Winkel, PhD. |
| Is Genmab publicy listed? | Yes, Genmab is a public company listed on CSE. |
| What is the stock symbol of Genmab? | Genmab trades under GMAB ticker. |
| When did Genmab go public? | Genmab went public in 2000. |
| Who are competitors of Genmab? | Similar companies to Genmab include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Genmab? | Genmab's current market cap is $12.8B |
| What is the current revenue of Genmab? | Genmab's last 12-month revenue is $3.4B. |
| What is the current EBITDA of Genmab? | Genmab's last 12-month EBITDA is $1.2B. |
| What is the current EV/Revenue multiple of Genmab? | Current revenue multiple of Genmab is 2.8x. |
| What is the current EV/EBITDA multiple of Genmab? | Current EBITDA multiple of Genmab is 8.2x. |
| What is the current revenue growth of Genmab? | Genmab revenue growth between 2023 and 2024 was 31%. |
| Is Genmab profitable? | Yes, Genmab is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
